Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched
This article was originally published in The Pink Sheet Daily
Executive Summary
After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.